Preclinical Screening Platforms
With the belief that developing treatments for schizophrenia shouldn’t rely on outdated and unreliable methods, our client aimed to revolutionise the process with an advanced preclinical platform that uses patient derived stem cells to predict therapeutic outcomes.
What did our client do?
Prior to this project, development of schizophrenia treatments have heavily relied on indirect testing models, often including animal models. This approach makes it difficult to predict clinical outcomes. Additionally, these treatments of old have failed to recognise and treat the genetic and physiological complexities of the disorder.
Aiming to approach the treatment of schizophrenia from a more patient driven angle, our clients underwent a research and development project that combined expertise in stem cell biology and advanced neural network modeling. After facing a range of challenges, the project culminated in the development of a groundbreaking preclinical platform that is set to pave the way for more effective and personalised treatment.
How did we help?
Upon reviewing the technical aspects of this research and development project, and assessing the intricate challenges in which the client had encountered, the specialist team at Alexander Clifford were confident that it would meet the eligibility criteria for R&D tax credit relief.
By engaging in collaborative technical discussions with the client, our team was able to identify key activities and eligible expenditure, while building an in depth technical report that detailed the fundamental project narrative. Compiling the sourced information, our team was then able to build a compliant R&D claim that presented the client with a substantial benefit.
